Literature DB >> 28516214

Interactions of cisplatin and the copper transporter CTR1 in human colon cancer cells.

Mia C Akerfeldt1, Carmen M-N Tran1, Clara Shen1, Trevor W Hambley1, Elizabeth J New2.   

Abstract

There is much interest in understanding the mechanisms by which platinum-based anticancer agents enter cells, and the copper transporter CTR1 has been the focus of many recent studies. While there is a clinical correlation between CTR1 levels and platinum efficacy, cellular studies have provided conflicting evidence relating to the relationship between cisplatin and CTR1. We report here our studies of the relationship between cisplatin and copper homeostasis in human colon cancer cells. While the accumulation of copper and platinum do not appear to compete with each other, we did observe that cisplatin perturbs CTR1 distribution within 10 min, a far shorter incubation time than commonly employed in cellular studies of cisplatin. Furthermore, on these short time-scales, cisplatin caused an increase in the cytoplasmic labile copper pool. While the predominant focus of studies to date has been on CTR1, these studies highlight the importance of investigating the interaction of cisplatin with other copper proteins.

Entities:  

Keywords:  Anticancer drug; Cisplatin; Copper; Metal transport

Mesh:

Substances:

Year:  2017        PMID: 28516214     DOI: 10.1007/s00775-017-1467-y

Source DB:  PubMed          Journal:  J Biol Inorg Chem        ISSN: 0949-8257            Impact factor:   3.358


  41 in total

Review 1.  Targeting copper in cancer therapy: 'Copper That Cancer'.

Authors:  Delphine Denoyer; Shashank Masaldan; Sharon La Fontaine; Michael A Cater
Journal:  Metallomics       Date:  2015-08-27       Impact factor: 4.526

2.  Prognostic value of the copper transporters, CTR1 and CTR2, in patients with ovarian carcinoma receiving platinum-based chemotherapy.

Authors:  Yoo-Young Lee; Chel Hun Choi; In-Gu Do; Sang Yong Song; Wooseok Lee; Hwang Shin Park; Tae Jong Song; Min Kyu Kim; Tae-Joong Kim; Jeong-Won Lee; Duk-Soo Bae; Byoung-Gie Kim
Journal:  Gynecol Oncol       Date:  2011-05-13       Impact factor: 5.482

3.  Enhancing tumor-specific uptake of the anticancer drug cisplatin with a copper chelator.

Authors:  Seiko Ishida; Frank McCormick; Karen Smith-McCune; Douglas Hanahan
Journal:  Cancer Cell       Date:  2010-06-15       Impact factor: 31.743

4.  A re-evaluation of the role of hCTR1, the human high-affinity copper transporter, in platinum-drug entry into human cells.

Authors:  Kristin D Ivy; Jack H Kaplan
Journal:  Mol Pharmacol       Date:  2013-03-29       Impact factor: 4.436

5.  A ratiometric fluorescent sensor for the mitochondrial copper pool.

Authors:  Clara Shen; Jacek L Kolanowski; Carmen M-N Tran; Amandeep Kaur; Mia C Akerfeldt; Matthew S Rahme; Trevor W Hambley; Elizabeth J New
Journal:  Metallomics       Date:  2016-08-23       Impact factor: 4.526

6.  Predictive and prognostic value of human copper transporter 1 (hCtr1) in patients with stage III non-small-cell lung cancer receiving first-line platinum-based doublet chemotherapy.

Authors:  Helen H W Chen; Jiang-Jou Yan; Wen-Chung Chen; Macus Tien Kuo; Yu-Hsuan Lai; Wu-Wei Lai; Hsiao-Sheng Liu; Wu-Chou Su
Journal:  Lung Cancer       Date:  2011-07-23       Impact factor: 5.705

7.  Cisplatin stabilizes a multimeric complex of the human Ctr1 copper transporter: requirement for the extracellular methionine-rich clusters.

Authors:  Yan Guo; Kathryn Smith; Michael J Petris
Journal:  J Biol Chem       Date:  2004-08-23       Impact factor: 5.157

Review 8.  The resurgence of platinum-based cancer chemotherapy.

Authors:  Lloyd Kelland
Journal:  Nat Rev Cancer       Date:  2007-07-12       Impact factor: 60.716

9.  Copper-stimulated endocytosis and degradation of the human copper transporter, hCtr1.

Authors:  Michael J Petris; Kathryn Smith; Jaekwon Lee; Dennis J Thiele
Journal:  J Biol Chem       Date:  2002-12-25       Impact factor: 5.157

10.  Cisplatin inhibits MEK1/2.

Authors:  Tetsu Yamamoto; Igor F Tsigelny; Andreas W Götz; Stephen B Howell
Journal:  Oncotarget       Date:  2015-09-15
View more
  10 in total

1.  Current Evidence on miRNAs as Potential Theranostic Markers for Detecting Chemoresistance in Colorectal Cancer: A Systematic Review and Meta-Analysis of Preclinical and Clinical Studies.

Authors:  Madhav Madurantakam Royam; Chellan Kumarasamy; Siddhartha Baxi; Ajay Gupta; Nachimuthu Ramesh; Gothandam Kodiveri Muthukaliannan; Rama Jayaraj
Journal:  Mol Diagn Ther       Date:  2019-02       Impact factor: 4.074

Review 2.  Application of Approved Cisplatin Derivatives in Combination Therapy against Different Cancer Diseases.

Authors:  Dobrina Tsvetkova; Stefka Ivanova
Journal:  Molecules       Date:  2022-04-11       Impact factor: 4.927

3.  A caged imidazopyrazinone for selective bioluminescence detection of labile extracellular copper(ii).

Authors:  Justin J O'Sullivan; Valentina Medici; Marie C Heffern
Journal:  Chem Sci       Date:  2022-03-23       Impact factor: 9.825

4.  The asymmetry of plasma membranes and their cholesterol content influence the uptake of cisplatin.

Authors:  Timothée Rivel; Christophe Ramseyer; Semen Yesylevskyy
Journal:  Sci Rep       Date:  2019-04-04       Impact factor: 4.379

5.  ATPase copper transporter A, negatively regulated by miR-148a-3p, contributes to cisplatin resistance in breast cancer cells.

Authors:  Ze Yu; Weifan Cao; Yuan Ren; Qijia Zhang; Jia Liu
Journal:  Clin Transl Med       Date:  2020-04-07

6.  Perftoran ® Inhibits Hypoxia-Associated Resistance in Lung Cancer Cells to Carboplatin.

Authors:  Amira M Gamal-Eldeen; Amani A Alrehaili; Afaf Alharthi; Bassem M Raafat
Journal:  Front Pharmacol       Date:  2022-03-24       Impact factor: 5.810

7.  Enhancer of zeste homolog 2 promotes cisplatin resistance by reducing cellular platinum accumulation.

Authors:  Si Sun; Simei Zhao; Qiang Yang; Wenwen Wang; E Cai; Yiping Wen; Lili Yu; Zehua Wang; Jing Cai
Journal:  Cancer Sci       Date:  2018-05-15       Impact factor: 6.716

8.  PTBP1 modulates osteosarcoma chemoresistance to cisplatin by regulating the expression of the copper transporter SLC31A1.

Authors:  Cheng Cheng; Qiuyue Ding; Zhicai Zhang; Shangyu Wang; Binlong Zhong; Xin Huang; Zengwu Shao
Journal:  J Cell Mol Med       Date:  2020-03-24       Impact factor: 5.310

Review 9.  The Drug-Resistance Mechanisms of Five Platinum-Based Antitumor Agents.

Authors:  Jiabei Zhou; Yu Kang; Lu Chen; Hua Wang; Junqing Liu; Su Zeng; Lushan Yu
Journal:  Front Pharmacol       Date:  2020-03-20       Impact factor: 5.810

Review 10.  Cellular Mechanisms Accounting for the Refractoriness of Colorectal Carcinoma to Pharmacological Treatment.

Authors:  Jose J G Marin; Rocio I R Macias; Maria J Monte; Elisa Herraez; Ana Peleteiro-Vigil; Beatriz Sanchez de Blas; Paula Sanchon-Sanchez; Alvaro G Temprano; Ricardo A Espinosa-Escudero; Elisa Lozano; Oscar Briz; Marta R Romero
Journal:  Cancers (Basel)       Date:  2020-09-11       Impact factor: 6.639

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.